Orbimed Advisors LLC Sells 142,500 Shares of Stryker Corporation $SYK

Orbimed Advisors LLC decreased its position in shares of Stryker Corporation (NYSE:SYK) by 43.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 182,500 shares of the medical technology company’s stock after selling 142,500 shares during the quarter. Stryker makes up approximately 1.1% of Orbimed Advisors LLC’s holdings, making the stock its 23rd largest holding. Orbimed Advisors LLC’s holdings in Stryker were worth $59,968,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in Stryker in the second quarter worth about $205,000. Marshall Wace LLP raised its holdings in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new stake in Stryker during the 2nd quarter worth about $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker during the 2nd quarter valued at about $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Stryker stock opened at $330.69 on Monday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $126.78 billion, a P/E ratio of 38.27, a PEG ratio of 2.12 and a beta of 0.77. The business has a 50-day moving average of $314.69 and a 200-day moving average of $335.57. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.14.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 14.99 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Wells Fargo & Company cut their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research note on Friday, May 1st. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 target price on shares of Stryker in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.